Welcome to our dedicated page for Milestone Scientific news (Ticker: MLSS), a resource for investors and traders seeking the latest updates and insights on Milestone Scientific stock.
Milestone Scientific, Inc. (NASDAQ: MLSS) is a pioneering company in the field of medical and dental anesthesia. The company focuses on the development, manufacture, marketing, and sale of computer-controlled local anesthetic delivery (C-CLAD) systems designed to provide improved and painless local anesthetic delivery. These systems are marketed under various trademarks for different applications. For dentistry, the products are known as CompuDent™ and STA™ (Single Tooth Anesthesia) System. These innovative devices allow for painless injections during a wide range of dental procedures, from routine cleanings to complex surgeries involving implants, root canals, and crowns.
For medical applications, Milestone Scientific offers similar technology under the CompuMed™ trademark. Their products are used across various medical disciplines, including plastic surgery, hair restoration surgery, podiatry, colorectal surgery, dermatology, and orthopedics. The company's advanced anesthetic delivery systems are sold both in the United States and in over 25 countries worldwide, highlighting their global reach and impact.
Besides their core product offerings, Milestone Scientific also provides The Wand™, a handpiece that allows for almost painless injections, enhancing patient comfort significantly.
The firm's operations are divided into two main segments: Dental and Medical. Geographically, all operations are concentrated in the United States, but their products are influential on a global scale.
Recent Achievements:
- Successful evaluations by prominent medical professionals, such as Dr. Matthew Stottle of Omaha Pain Physicians, achieving 100% success rates.
- Acceleration in reimbursement claims submission for the CompuFlo® Epidural System.
For more information or inquiries, Milestone Scientific can be contacted through Crescendo Communications, LLC via email at mlss@crescendo-ir.com or by phone at 212-671-1020.
Milestone Scientific Inc. (NYSE: MLSS) is set to participate in The MicroCap Rodeo’s 2nd Annual Winter Wonderland Best Ideas Conference from February 8-11, 2022. CEO Arjan Haverhals will present on February 9 at 10:30 AM ET. The presentation can be accessed via webcast on the company's website. The conference includes 25-minute virtual presentations and one-on-one meetings for investors. This event showcases qualified institutional investors' best ideas.
Milestone Scientific (NYSE: MLSS) announced that CEO Arjan Haverhals will participate in a virtual fireside chat on January 20, 2022, hosted by Maxim Group's Anthony Vendetti. This event aims to provide insights into Milestone's advanced computerized drug delivery technology, which ensures painless and precise injections. Investors can view the live webcast at 11:00 a.m. EST, with a replay available for 48 hours afterward. Milestone is focused on enhancing patient comfort and safety through its innovative DPS Dynamic Pressure Sensing Technology®.
Milestone Scientific (NYSE: MLSS) reports anticipated revenues over $2.6 million for Q4 2021, up from $2.2 million in Q4 2020, and over $10 million for FY 2021, a significant increase from $5.4 million in FY 2020. CEO Arjan Haverhals highlights growth in dental and medical divisions, with successful marketing efforts and new distributors contributing to an 85% revenue increase. The company expresses confidence in its future, citing a strong balance sheet and a substantial market opportunity in the U.S. for epidural analgesia, estimated at over $5 billion annually.
Milestone Scientific (NYSE:MLSS) recently announced that CEO Arjan Haverhals will present at the H.C. Wainwright BioConnect 2022 Conference, which occurs virtually from January 10-13, 2022. The presentation will be available on-demand starting January 10 at 7:00 AM Eastern Time for registered attendees. Milestone Scientific specializes in developing computerized drug delivery instruments aimed at providing painless injections, enhancing patient comfort and safety through innovative DPS Dynamic Pressure Sensing Technology.
Milestone Scientific (NYSE:MLSS) has expanded into the pain management market with the incorporation of the CompuFlo Epidural instrument by Dr. Harsh Govil in his practice in Statesville, NC. This decision follows a successful evaluation and aims to enhance patient safety and efficacy in pain management procedures. Arjan Haverhals, CEO, emphasized the growing traction in this sector, noting over 11 million annual epidural procedures in the U.S. Milestone aims to advance its technology beyond labor and delivery into broader applications in pain management.
Milestone Scientific (NYSE: MLSS) has announced the purchase of CompuFlo Epidural and CathCheck Verification System disposables from two prominent hospitals, enhancing its market presence. CEO Arjan Haverhals highlighted that these orders mark significant progress as both hospitals are part of large healthcare systems. The technology reportedly improves safety, efficiency, and offers economic advantages. Published studies support the technology's effectiveness, potentially reducing costs and complication rates associated with procedures.
Milestone Scientific (NYSE:MLSS) has announced a new agreement with Andau Medical to distribute its STA Single Tooth Anesthesia System in the U.S. and Canada. This partnership aims to enhance the dental experience by providing painless injections, reducing wait times, and minimizing complications. CEO Arjan Haverhals expressed optimism about the collaboration, noting Andau's strong track record in the dental market. Andau Medical’s founder, Sandi Wright, highlighted the system’s benefits for both patients and clinicians.
Milestone Scientific (NYSE:MLSS) has signed an agreement with a prestigious Northeast teaching hospital for the purchase of its CompuFlo® Epidural and CathCheck™ Verification System disposables. This follows a successful trial demonstrating the technology's safety and efficacy, enhancing accuracy in epidural procedures. The CompuFlo system is expected to reduce healthcare costs associated with morbidity and significantly decrease monitoring time for catheter placements. The company aims to expand its reach beyond labor and delivery, targeting pain management and outpatient centers.
Milestone Scientific (NYSE:MLSS) announced that CEO Arjan Haverhals will present at the Benzinga All Access event on December 16, 2021, at 10:40 A.M. Eastern Time. The presentation will recap key activities from 2021 and outline the company's sales pipeline and goals for 2022. The event will be broadcast live, and an archived recording will be accessible on Milestone's investor relations website. Milestone Scientific is known for its computerized drug delivery instruments, enhancing patient comfort and safety with innovative technologies.
Milestone Scientific (NYSE:MLSS) announced a significant step in expanding its CompuFlo Epidural instrument into the pain management market. Dr. Miguel de la Garza has started using the instrument in his practice, following approval by Surgery Partners, enhancing safety in procedures with reduced risk of complications. The overall addressable market for epidural anesthesia is around $5 billion, with pain management being twice the size of labor and delivery. CEO Arjan Haverhals emphasized the potential for capturing a significant market share with this innovative technology.
FAQ
What is the current stock price of Milestone Scientific (MLSS)?
What is the market cap of Milestone Scientific (MLSS)?
What does Milestone Scientific, Inc. do?
What are the main products offered by Milestone Scientific?
Where are Milestone Scientific’s products sold?
What recent achievements has Milestone Scientific accomplished?
What are the main segments of Milestone Scientific’s business?
How can Milestone Scientific be contacted?
What is The Wand™?
What is the STA™ System?
Which medical disciplines use Milestone Scientific’s systems?
What is CompuMed™?
